Indian Gene + Cell Therapy Facility MEP — USFDA 21 CFR 1271 + EU EMA Annex 1 + ICH Q5 + ImmunoACT

A 200 patient-doses/year Indian autologous CAR-T facility (ImmunoACT-class) demands ₹824 Cr MEP capex with apheresis room + Grade A LAF in B viral-vector transduction + closed-system bioreactor + cryopreservation + LIMS chain-of-identity + Class II BSC. USFDA 21 CFR 1271 + EU EMA Annex 1 + ICH Q5 + Schedule M + FACT-JACIE govern. Indian CAR-T cost ₹25L/patient vs international ₹3 Cr+. Three failures: open vs closed-system inconsistent, chain-of-identity manual paper instead of LIMS + 21 CFR 11, cryopreservation in liquid LN2 instead of vapour-phase causing contamination.

Indian gene + cell therapy facility framework

India advanced therapy — IndImmuno (Bharat Biotech) + ImmunoACT (autologous CAR-T) + ICGEB + Mylab + Indian Council of Medical Research IND filings. Cell + gene therapy (CGT) demands Grade A LAF + isolator + biosafety cabinet + viral-vector closed-system + cleanroom-in-cleanroom architecture. Standards stack — USFDA 21 CFR 1271 (HCT/P) + EU GMP Annex 1 + Schedule M 2023 + ICH Q5A + Q5D + India RCGM + DBT + CDSCO + ATMP-specific guidelines + USP 1071 + 1079 + 1090.

Autologous CAR-T cell therapy facility MEP scope — 200 patient-doses/year

Three Indian CGT facility MEP failures

1. Open vs closed-system not consistent — autologous CGT requires either fully-closed system OR Grade A LAF in B at every open step. Indian facilities sometimes mix — fails USFDA + EMA cGMP inspection.
2. Chain-of-identity + chain-of-custody documentation gaps — autologous CGT cannot tolerate sample mix-up = patient harm. Specify LIMS with barcode + electronic-signature + 21 CFR Part 11 compliance. Indian R&D often paper-based + manual.
3. Cryopreservation controlled-rate freezing + vapour-phase LN2 — viable cell preservation requires -1°C/min cooling rate + < -150°C storage in vapour-phase LN2 (cross-contamination risk in liquid). Indian facilities sometimes use liquid LN2 = contamination + thawing failure.